Pulse Biosciences (NASDAQ:PLSE) Trading Down 5.9% - Time to Sell?

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) dropped 5.9% on Friday . The company traded as low as $16.25 and last traded at $16.12. Approximately 17,733 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 177,238 shares. The stock had previously closed at $17.12.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PLSE. Oppenheimer started coverage on shares of Pulse Biosciences in a research report on Monday, July 7th. They set an "outperform" rating and a $22.00 target price on the stock. Wall Street Zen upgraded shares of Pulse Biosciences to a "sell" rating in a research report on Monday, March 31st.

Pulse Biosciences Stock Performance

The firm has a 50 day moving average price of $16.32 and a 200-day moving average price of $17.45.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, CTO Darrin Uecker sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $16.40, for a total value of $246,000.00. Following the transaction, the chief technology officer directly owned 137,872 shares of the company's stock, valued at approximately $2,261,100.80. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 71.50% of the stock is currently owned by company insiders.

Institutional Trading of Pulse Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its stake in shares of Pulse Biosciences by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock worth $2,598,000 after purchasing an additional 1,092 shares during the period. Farther Finance Advisors LLC boosted its holdings in Pulse Biosciences by 44.4% during the fourth quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company's stock worth $126,000 after buying an additional 2,220 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Pulse Biosciences during the 4th quarter worth about $44,000. Vanguard Group Inc. increased its stake in shares of Pulse Biosciences by 15.1% in the 4th quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company's stock valued at $19,958,000 after acquiring an additional 150,506 shares during the last quarter. Finally, Caisse Des Depots ET Consignations bought a new stake in shares of Pulse Biosciences in the 4th quarter valued at about $95,000. Institutional investors own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.